Biotech companies have been some of the hottest IPOs in recent years. Last year, biotech company Moderna (MRNA) went public raising a biotech record of $604 million.

近年来，生物科技公司进行的IPO一直非常热门。去年，生物科技公司Moderna (MRNA)通过IPO融资6.04亿美元，规模创下该行业纪录。

For the average investor, though, it’s nearly impossible to understand what these companies actually do.

然而对于普通投资者而言，这些公司的具体业务非常难懂。

Many of the Wall Street analysts covering these companies have phds and MDs. And their reports are not exactly easy reading. But that doesn’t mean there aren’t big opportunities, certainly for humanity and sometimes for investors

跟踪研究这些公司的许多华尔街分析师都拥有博士和医学博士学位，普通投资者很难读懂他们的研报。但这并不意味着该领域投资机会不多，生物科技当然对人类健康非常有益，但有时对投资者来说也是有利可图的。

This week on The Readback, Barron’s healthcare reporter Josh Nathan-Kasiz joins Alex Eule to discuss his recent cover story on one promising biotech treatment called messenger RNA, or mRNA.

在本期的The Readback中，《巴伦》医疗保健行业记者 乔希·内森-卡吉斯(Josh Nathan-Kazis)和亚历克斯·尤勒(Alex Eule)一起讨论了他在最新封面文章中谈到的一种很有前景的生物科技疗法，这种疗法被称为信使核糖核酸(mRNA)疗法。

The four biotech companies leading the research on the idea have attracted more than $5 billion in capital. And some of that investment has come from the biggest names in Big Pharma: Merck (MRK), Sanofi (SNY), AstraZeneca(AZN), and GlaxoSmithKline (GSK).

牵头对这一疗法进行研究的四家生物科技公司已经吸引了超过50亿美元的资金。其中一些投资来自以下四家大型制药公司：默克(Merck, MRK)、赛诺菲(Sanofi, SNY)、阿斯利康(Astrazeneca, AZN)和葛兰素史克(GlaxoSmithKline, GSK)。

The Readback is a financial podcast published every Wednesday. 

The Readback是一档每周更新一次的金融类播客栏目。

翻译 | Anqi

版权声明：

《巴伦》(barronschina) 原创文章，未经许可，不得转载。英文版见2019年9月5日报道“Podcast: Why Big Pharma Is Betting on a New Biotech Therapy”。

（本文内容仅供参考，投资建议不代表《巴伦》倾向；市场有风险，投资须谨慎。）